SCHEMBL4629301

SCHEMBL4629301

CC(C)c1ccc(N=C(N)NC(=O)Cc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.58
SCN2A Q99250 2/20 0.55
SCN5A Q14524 1/20 0.55
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CACNA1G O43497 1/20 0.46
CACNA1H O95180 1/20 0.46
CACNA1I Q9P0X4 1/20 0.46
CTSD P07339 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CNR1 P21554 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628762 0.83 CNR2 (0.60) CNR2SCN2ASCN5ARAB9ACTSD
SCHEMBL4628685 0.81 ALDH1A1 (0.56) SCN2AALDH1A1RAB9ACTSDNLRP3
SCHEMBL4629406 0.81 SCN2A (0.78) SCN2ASCN5AGRIN2DGRIN3BGRIN1
SCHEMBL4628743 0.77 SCN2A (0.67) SCN2AALDH1A1RAB9ANOS3NOS1
SCHEMBL4627515 0.76 SCN2A (0.60) SCN2ASCN5AGRIN2DGRIN3BGRIN1
SCHEMBL4629388 0.75 SCN2A (0.64) SCN2ASCN5AGRIN2DGRIN3BGRIN1
SCHEMBL5300654 0.74 RAB9A (0.73) CNR2ALDH1A1RAB9ACACNA1GCACNA1H
SCHEMBL15064374 0.74 CNR2 (1.00) CNR2CNR1
SCHEMBL4629299 0.73 RAB9A (0.59) CNR2ALDH1A1RAB9ACACNA1GCACNA1H
SCHEMBL4629297 0.73 SCN5A (0.62) SCN2ASCN5AGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA CNR2 571/4885SCN2A 1613/4885SCN5A 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.